手握三个BD大热,Biotech龙头被低估

瞪羚社
Jun 09, 2025

上方“瞪羚社”即刻关注并加入社群聚焦高成长公司,100000+投资菁英共同关注当年的国产“PD-1四小龙”今何在?百济凭借泽布替尼出海一只脚踏进盈利大门,恒瑞转型创新药批量出海加A+H上市风光无限,信达手握玛仕度肽和潜在PD-1/IL-2大药被市场捧在手心,唯独君实生物好像被困在时光里。过去仅仅代表过去,2025年君实生物迎来反转之势,尽管在这波创新药β行情中相对滞涨,但公司的后劲十足,核心逻辑是...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10